+ Biopure Corporation Case Analysis Back Bay Xue Yang + Agenda 1. Current Situation 2. SWOT Analysis 3. Quantitative Analysis 4. Recommendations + Current SituationBiopure Corporation The main objectives of Biopure Corporation is blood substitutes development There are 2 products: Oxyglobin and Hemopure. Oxyglobin is targeting at veterinary market and Hemopure is targeting at human market The company has spent $200 million on R&D of Hemopure Oxyglobin has already approved
Premium Variable cost Blood Marketing
Course: Biopure Corporation 1. Decision: Biopure should launch Oxyglobin at a price of $200 immediately in the market. The early introduction of Oxyglobin may jeopardize the ability to set a high price for Hemopure‚ but the benefits of introduction will outweigh the risks. 2. Recommendation: Biopure should price Oxyglobin at $200 per unit. At the same time‚ it should enlarge the production capacity as soon as possible to satisfy the potential market demand for Hempure. As for the distribution
Premium Blood Blood transfusion
BIOPURE Corporation. 1. Give your best estimate of the sizes of Biopure’s market‚ potential market‚ and what you recommend as the target market in the animal market? Do the same for the human blood market? Who are these people (or animals)? Since the definitions of these different markets can be vague‚ it may be useful to operationalize these concepts in terms of circles on a target which represent the likelihood of being a customer and when they should be targeted by the company. Thus‚ the “target
Free Blood Blood transfusion Surgery
Andrew Walters 3/22/12 Biopure Biopure Corporation specializes in blood substitutes for transfusion patients‚ both in the veterinary market and the human market. However‚ in 1998‚ Biopure faced the monumental decision of whether to begin selling Oxyglobin‚ a blood substitute‚ to the veterinary market or to wait until Hemoglobin‚ a blood substitute for the human market‚ became available for sale. The problem is whether or not the company should launch Oxyglobin before Hemoglobin is FDA-approved
Premium Blood transfusion Blood
I will examine the challenges faced by Biopure in sequencing the release of 2 drugs. One ‚Oxyglobin‚ is ready for the Veterinary Market‚ and the other‚ Hemopure‚ whose success could rely on the brand management of the former. I will look at issues related to the success of the company and make the recommendation to launch Oxyglobin now. Currently Biopure creates blood products for two markets‚ human and veterinary. While Oxyglobin is ready to release for the veterinary market‚ Hemopure is 2 years
Premium Blood Blood transfusion
INTRODUCTION In the case of Biopure‚ the issue is to decide whether to launch Oxyglobin and how to launch it without jeopardizing the potential of Hemopure. Oxyglobin is a substitute to animal blood while Hemopure is a substitute to human blood. The CEO need to identify the influence of the launch of Oxyglobin bring to Hemopure. If the company is launching Oxyglobin‚ the CEO need to decide the price‚ identify the target client‚ choose distributing method and consider the production capacity. The
Free Blood Blood transfusion Veterinary medicine
BIOPURE CASE SUMMARY Course: Strategic Marketing Management Name: Firat Sekerli The Problem: Biopure Corporation has two new products that are Oxyglobin and Hemopure. Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use. Hemopure is another new blood substitute for the human market and it will take two years to launch the product from now on. Ted Jacobs‚ vice president for Human Clinical
Premium Marketing Blood transfusion Blood
recommendation that Biopure should immediately launch Oxyglobin. The reasons for this decision are as followed: Obtaining the Monopoly on blood substitutes - If Biopure waits to launch Oxyglobin they will miss a prime opportunity to control the blood substitute market‚ especially the animal market. As mentioned in the case‚ Biopure’s competitors have yet to launch their products. Furthermore‚ Baxter International and Northfield Laboratories do not have an animal substitute for Biopure to compete with1
Premium Blood transfusion Blood Marketing
UNDERSTANDING THE CASE PROCESS INTRODUCTION The purpose of this section is to help you to understand what a case is and how you‚ as a student of business‚ can more effectively prepare your answers and benefit from a case discussion. The material covered in this section includes: 1. Understanding what a case is. 2. Reading a case effectively. 3. Analysing and preparing for a case discussion. 4. Reporting your case findings. 5. Discussing the case. 1. Understanding what a case is. Socrates
Premium Problem solving The Key
& PRESENT YOUR ESOURCING BUSINESS CASE MAY 17‚ 2011 Can’t attend ISM’s 96th annual International Supply Management Conference this week? Don’t worry; we have some helpful notes from the conference to share with you. Lauren Panza‚ managing director of the greater Atlanta area for Iasta‚ attended the presentation‚ “Indirect Purchasing: Getting a Seat at the Table” yesterday morning. The presentation outlined how to build and present a strong business case to executives for indirect sourcing projects
Premium Success Management The Table